Executive Summary: A New Frontier in Preventive Diagnostics
In a significant move to reshape the landscape of preventive healthcare in Southeast Europe, Finnish health-tech innovator Nightingale Health has officially entered the Croatian market. Through a strategic partnership with the regional healthcare provider Genom, the company is set to deploy its advanced blood-based risk detection test—the "Nightingale Health Check"—across an extensive network of clinics and laboratories.
The collaboration represents a paradigm shift in how chronic diseases are managed. By utilizing a single, comprehensive blood sample, the test provides a ten-year predictive risk estimate for five major chronic conditions: heart attack, type 2 diabetes, ischaemic stroke, chronic kidney disease, and fatty liver disease. This partnership, which follows successful pilot programs in the region, aims to empower clinicians with data-driven insights, moving the medical focus from reactive treatment to proactive, personalized prevention.
The Technology: Decoding Long-Term Health Risks
At the heart of this partnership is the Nightingale Health Check, a proprietary diagnostic solution that leverages advanced metabolomics. Unlike traditional blood tests that often focus on isolated biomarkers, the Nightingale platform analyzes a comprehensive profile of metabolic health markers from a single sample.
The Five-Pillar Risk Assessment
The clinical utility of the test lies in its ability to offer a holistic outlook on a patient’s health trajectory over the coming decade. By identifying underlying metabolic imbalances, the test flags risks for:
- Cardiovascular Health: Early detection of risks associated with heart attack and ischaemic stroke.
- Metabolic Syndrome: Precision screening for type 2 diabetes.
- Organ Health: Longitudinal monitoring for chronic kidney disease and non-alcoholic fatty liver disease.
The process is seamless for both the provider and the patient. After the blood is collected within the Genom network, samples are processed and analyzed using Nightingale’s high-throughput technology. The resulting reports are delivered back to the clinicians, who interpret the findings through the lens of established medical guidelines to create tailored preventive pathways for patients.
Chronology of Collaboration: From Pilots to Nationwide Rollout
The entry into the Croatian market was not a spontaneous decision but the result of a deliberate, data-backed strategy.
1. The Exploratory Phase (Early 2026)
Recognizing the growing demand for preventive diagnostics in the Mediterranean and Balkan regions, Nightingale Health began assessing potential partners in Croatia. The company sought an established local entity with a deep-rooted infrastructure and a commitment to clinical excellence.
2. The Pilot Programs
Prior to the full-scale commercial launch, three distinct pilot programs were conducted across various clinics and laboratories within the Genom network. These pilots served a dual purpose: they validated the operational logistics of sample collection and transportation, and they measured the appetite of the Croatian medical community for advanced metabolic screening. The results were overwhelmingly positive, showing high clinician engagement and patient interest.
3. The Official Partnership Agreement (Q3 2026)
Following the success of the pilots, Nightingale Health and Genom formalized their collaboration. The agreement dictates that Genom will act as the primary interface with healthcare providers, while Nightingale will provide the sophisticated laboratory infrastructure and data analytics engine.
4. Current Status: The 2026 Rollout
With the infrastructure now in place, the rollout of the Nightingale Health Check across the entire Genom network is scheduled for the remainder of 2026. This expansion is designed to reach both urban centers and rural clinics, ensuring equitable access to advanced diagnostic tools.
Strategic Implications: Why This Matters for Croatia
The introduction of this technology is particularly timely. Across Europe, healthcare systems are under increasing pressure from an aging population and the rising prevalence of non-communicable diseases (NCDs). Croatia is no exception to these global trends.
Addressing the Chronic Disease Burden
Chronic diseases are the leading cause of mortality and morbidity in Croatia. Currently, many of these conditions are only diagnosed once symptoms appear, often requiring invasive or expensive treatment regimens. By identifying "at-risk" individuals years before the onset of clinical symptoms, the Nightingale Health Check allows for early lifestyle interventions—such as dietary changes, exercise programs, and targeted medical therapy—that can significantly mitigate or even prevent the onset of severe disease.
Empowering the Clinician
One of the most common challenges in primary care is the lack of objective, longitudinal data to guide patient counseling. Clinicians often rely on static snapshots of a patient’s health. With the Nightingale Health Check, doctors receive a comprehensive risk report that serves as a conversation starter, allowing for more impactful, data-informed consultations.
Perspectives from Leadership
The partnership has been met with enthusiasm from both organizations, reflecting a shared vision of a more "preventive-first" healthcare ecosystem.
Maja Barbalić, CEO and founder of Genom, emphasized the importance of accessibility:
"Our goal has always been to make innovative healthcare solutions accessible through trusted healthcare providers. The Nightingale Health Check complements our existing portfolio by providing healthcare professionals with a scientifically validated tool for earlier identification of chronic disease risk and more personalized preventive care."
Teemu Suna, CEO and founder of Nightingale Health, highlighted the strength of the local partnership:
"Genom gives us an established route into Croatian healthcare, with a network of clinics and laboratories that are ready to use the Nightingale Health Check. Three completed pilots and demand from both clinics and laboratories show that the market is positive about our test. With a partner of Genom’s standing and reach, we have a strong foundation to build on in Croatia."
Contextualizing Growth: Nightingale’s European Expansion
This expansion into Croatia is part of a broader, aggressive growth strategy for Nightingale Health. The company has spent the last 18 months systematically strengthening its footprint across the Nordic and European markets.
Notably, in November 2025, the company secured a landmark agreement with Terveystalo, one of the largest private healthcare providers in the Nordic region. That partnership extended the use of Nightingale’s blood analysis technology to all of Terveystalo’s customer segments, signaling a maturation of the technology from a niche offering to a standard-of-care tool.
The Croatian launch serves as a blueprint for Nightingale’s strategy in other emerging markets. By leveraging existing local networks rather than building from scratch, the company can rapidly scale its impact, proving that the technology is adaptable to different healthcare systems, regulatory environments, and patient demographics.
Future Outlook: The Role of Data in Preventive Medicine
As the rollout progresses through the end of 2026, the data gathered from the Croatian market will be closely monitored. The long-term objective for Nightingale Health is to build a "health map" that can eventually inform public health policy.
Furthermore, the integration of these tests into the Genom network is expected to yield valuable insights into the efficacy of early intervention programs. If successful, this model could be expanded to include more conditions or integrated into national screening initiatives.
Conclusion
The partnership between Nightingale Health and Genom is more than a commercial agreement; it is a vital step toward a more sustainable healthcare future for Croatia. By bridging the gap between cutting-edge metabolic research and routine clinical practice, the two companies are providing the tools necessary to move from the management of sickness to the maintenance of health. As the rollout gains momentum, the focus will shift to how this data can best be translated into clinical outcomes, setting a new benchmark for preventive medicine in the region.
About the Author
